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Gene Transfer of Engineered Calmodulin Alleviates Ventricular
Arrhythmias in a Calsequestrin-Associated Mouse Model of
Catecholaminergic Polymorphic Ventricular Tachycardia
Bin Liu, PhD;* Shane D. Walton, PhD;* Hsiang-Ting Ho, PhD; Andriy E. Belevych, PhD; Svetlana B. Tikunova, PhD; Ingrid Bonilla, PhD;
Vikram Shettigar, PhD; Bjorn C. Knollmann, MD, PhD; Silvia G. Priori, MD, PhD; Pompeo Volpe, MD; Przemysław B. Radwanski, PharmD,
PhD; Jonathan P. Davis, PhD†; Sandor Gy€orke, PhD†
Background-—Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial arrhythmogenic syndrome characterized
by sudden death. There are several genetic forms of CPVT associated with mutations in genes encoding the cardiac ryanodine
receptor (RyR2) and its auxiliary proteins including calsequestrin (CASQ2) and calmodulin (CaM). It has been suggested that
impairment of the ability of RyR2 to stay closed (ie, refractory) during diastole may be a common mechanism for these diseases.
Here, we explore the possibility of engineering CaM variants that normalize abbreviated RyR2 refractoriness for subsequent viral-
mediated delivery to alleviate arrhythmias in non–CaM-related CPVT.
Methods and Results-—To that end, we have designed a CaM protein (GSH-M37Q; dubbed as therapeutic CaM or T-CaM) that
exhibited a slowed N-terminal Ca dissociation rate and prolonged RyR2 refractoriness in permeabilized myocytes derived from
CPVT mice carrying the CASQ2 mutation R33Q. This T-CaM was introduced to the heart of R33Q mice through recombinant adeno-
associated viral vector serotype 9. Eight weeks postinfection, we performed confocal microscopy to assess Ca handling and
recorded surface ECGs to assess susceptibility to arrhythmias in vivo. During catecholamine stimulation with isoproterenol, T-CaM
reduced isoproterenol-promoted diastolic Ca waves in isolated CPVT cardiomyocytes. Importantly, T-CaM exposure abolished
ventricular tachycardia in CPVT mice challenged with catecholamines.
Conclusions-—Our results suggest that gene transfer of T-CaM by adeno-associated viral vector serotype 9 improves myocyte Ca
handling and alleviates arrhythmias in a calsequestrin-associated CPVT model, thus supporting the potential of a CaM-based
antiarrhythmic approach as a therapeutic avenue for genetically distinct forms of CPVT. ( J Am Heart Assoc. 2018;7:e008155.
DOI: 10.1161/JAHA.117.008155.)
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C ardiac arrhythmia is a leading cause of mortality andmorbidity worldwide.1,2 Aberrant Ca handling, and alter-
ations in the cardiac sarcoplasmic reticulum (SR) Ca release
channel (ryanodine receptor, RyR2), in particular, is recog-
nized as an important factor in the genesis of arrhythmia.3,4
This link is especially evident in catecholaminergic
polymorphic ventricular tachycardia (CPVT), an inherited
arrhythmic syndrome caused by mutations in the RyR2 itself
and its multiple accessory proteins including calsequestrin 2
(CASQ2) and calmodulin (CaM).5,6
Interestingly, previous work from our and other laborato-
ries have demonstrated that impairment of the ability of RyR2
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to become refractory, ie, appropriately close after each
systolic Ca release event, appears to be a common mecha-
nism for various forms of genetic and acquired arrhythmias,
including CPVT and post-infarction ventricular ﬁbrillation
(VF).7–9 Speciﬁcally, shortened RyR2 refractoriness results
in aberrant diastolic SR Ca release that synchronizes across
the myocardium to induce triggered activity, thus, precipitat-
ing malignant arrhythmias.
Given its central role in Ca-dependent arrhythmias, RyR2 is a
logical target for the treatment of these arrhythmias.10–14
However, the development of effective and safe RyR2 based
therapies is hindered by the complex nature of RyR2 regulation
and myocyte Ca handling. For example, most of the current
RyR2 targeting compounds act by reducing the overall RyR2
open probability (during both systole and diastole) making
them inefﬁcient or even detrimental in patient groups with
impaired systolic function. The ideal RyR2 “blocker” would be
one that allows normal Ca release during systole, but becomes
inhibited only during diastole, ie, refractory. In other words, the
blocker would speciﬁcally target the refractory window of RyR2
to prevent aberrant diastolic Ca release.
CaM is a cytosolic Ca binding protein that translates
changes in Ca concentrations into changes in function of
target proteins including RyR2.15,16 In cardiac cells, most CaM
is bound to RyR2 and inhibits its activity in a Ca-dependent
manner.17–20 Such Ca dependent binding would be expected
to inhibit RyR2 speciﬁcally after Ca release lasting late into
the diastolic period. Consistent with this notion, mutations in
CaM have recently been linked to CPVT, a syndrome
associated with a shortened RyR2 refractory period.7,8,21 We
reasoned that if indeed certain CPVT-causing CaM mutations
act by shortening RyR2 refractoriness, then CaM variants with
slowed Ca dissociation could be engineered to prolong RyR2
refractoriness in cardiac disease settings when refractoriness
is pathologically shortened. Such therapeutic CaMs poten-
tially could be applied to alleviate aberrant Ca release and the
resulting arrhythmias caused not only by mutations in CaM
but possibly other genetic and acquired defects in the RyR2
complex.
In this study, we demonstrate that RyR2 refractoriness can
indeed be directly modulated through altering the N-terminal
Ca exchange rates of CaM. Importantly, here we present a
genetically engineered CaM that when applied via a viral
delivery system, restores RyR2 refractoriness and relieves
arrhythmia burden in vivo in a mouse model of CPVT caused by
amutation in another component of the RyR2 complex, CASQ2.
Methods
The data and analytic methods will be made available to other
researchers for purposes of reproducing the results or
replicating the procedure. The data that support the ﬁndings
of this study are available from the corresponding author on
reasonable request.
Ethical Approval
All animal procedures were approved by the Ohio State
University Institutional Animal Care and Use Committee. The
study conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 2011).
Mouse Models
CASQ2 R33Q22 and knock out (KO)23 mice (3–6 months old,
males) in the C57BL/6 genetic background were utilized in
this study. All animal procedures were approved by The Ohio
State University Institutional Animal Care and Use Committee.
The study conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 2011).
Virus Production and Injection
Adeno- associated viral vector serotype 9 (AAV9) vectors were
produced by co-transfecting HEK293 cells with three plasmids
as previously described,24 which were then expanded in 10%
DMEM medium. Five days after transfection, the cells were
Clinical Perspective
What Is New?
• Catecholaminergic polymorphic ventricular tachycardia is a
life threatening inherited arrhythmia syndrome caused by
mutations in the ryanodine receptor (RyR2) and its auxiliary
proteins including calsequestrin 2 (CASQ2) and calmodulin
(CaM).
• The underlying cause of catecholaminergic polymorphic
ventricular tachycardia involves the compromised ability of
RyR2 to stay closed during diastole thereby resulting in
aberrant arrhythmogenic intracellular Ca release.
• Here we designed a CaM construct that combines enhanced
Ca sensitivity with tighter RyR2 binding resulting in
enhanced Ca-dependent inhibition of RyR2.
What Are the Clinical Implications?
• Gene transfer of this CaM construct (therapeutic CaM,
TCaM) normalized myocyte Ca cycling and alleviated life-
threatening arrhythmias in vivo in mice affected by a
mutation within another disease-related protein (CASQ2).
• Thus, TCaMs may provide a therapeutic strategy for multiple
genetic forms of catecholaminergic polymorphic ventricular
tachycardia.
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harvested for downstream puriﬁcation using PEG precipitation
and an iodixanol gradient protocol.25 The 40% iodixanol
gradient band was collected and subjected to further
puriﬁcation. The virus titer was obtained via TaqMan
(LifeTechnologies) based quantiﬁcation. AAV9 (100 lL, con-
taining 191011 viral genomes) was injected into adult male
mice (12–14 weeks old) through the intra-thoracic cavity.
After being lightly anaesthetized by 1% isoﬂurane, mice were
kept in supine position to allow clear access to the chest area.
A needle (29.5 gauge) was then inserted at an angle halfway
between the ribs and 7.5 mm left of sternum. Care was
taken to avoid insertion of the needle into the lungs or heart.
This straightforward technique ensures efﬁcient and highly
reproducible viral transduction speciﬁcally to the adult heart,
meanwhile minimizing the risk of damaging the beating
heart.24
Measurement of the Rate of Ca Dissociation From
CaM
Wild type (WT) and recombinant CaM were expressed in
bacteria (DE3 BL21) and puriﬁed as previously described.26
Ca dissociation rates were measured using an Applied
Photophysics Ltd. (Leatherhead, UK) model SX.18 MV
stopped-ﬂow instrument with a dead time of 1.4 ms at
20°C. Each rate represents an average of at least ﬁve traces.
CaMF20W was utilized to record the rate of Ca dissociation
from the N-terminal domain of isolated CaM,26 the samples
were excited using a 150 W xenon arc source. The tryptophan
(Trp) emission was monitored through a UV-transmitting black
glass ﬁlter (UG1 from Oriel [Stanford, CT]). The data collected
from CaMF20W were ﬁt with a single exponential. Each koff
represents an average of at least ﬁve traces. The ﬂuorescent
Ca chelator Quin-2 was utilized to record the rate of Ca
dissociation from CaM in the presence of the human RyR2
CaM-binding domain (RSKKAVWHKLLSKQRKRAVVACFRMA-
PLYNL). Data were ﬁt with a double exponential (variance less
than 1.39104) to account for the fact that Quin-2 reports the
rates of Ca dissociation from both the N- and C-domains of
CaM. The buffer used in all stopped-ﬂow experiments was
10 mmol/L MOPS, 150 mmol/L KCl, pH 7.0.
Electrocardiographic Recordings
After the mice were lightly anesthetized by isoﬂurane,
baseline ECG was recorded for 5 minutes, followed by an
additional 10 minutes after the administration of the a and
b-agonists epinephrine (EPI, 1.5 mg/kg) and caffeine
(120 mg/kg) via intraperitoneal (IP) injection.27 ECG traces
were analyzed using LabChart 7 Pro (AD Instruments). The
mice utilized for the ECG recordings were not used for other
experiments.
Cardiomyocyte Isolation and Confocal Ca Imaging
Myocyte isolation
Mice were fully anesthetized using 4% isoﬂurane in 95% oxygen,
before surgically removing the heart. Mouse ventricular
myocytes were isolated as previously described.28,29 Brieﬂy,
the heartswere quickly excised andperfused on a Langendorff’s
apparatus at 37°C. After 5 minutes of perfusion with nominally
Ca-free perfusion solution (containing, in mmol/L: 140 NaCl,
5.4 KCl, 0.5 MgCl2, 10 Hepes, and 5.6 glucose [pH 7.3]), the
perfusate was switched to perfusion solution containing
Liberase TH (0.24 U; Roche) for the digestion of the connective
tissue. After digestion, single ventricular myocytes were
isolated from the dissected and triturated ventricles and
stabilized in perfusion solution containing BSA (20 mg/mL).
Ca imaging in intact myocytes
The ventricular myocytes were loaded with 8 lmol/L Fluo-3
AM (Invitrogen, Carlsbad, CA) for 25 minutes at room
temperature, followed by 25 minutes of incubation in fresh
perfusion solution (de-esteriﬁcation). Fluo-3 was excited with
the 488 nm line of an argon laser and emission was collected
at 500 to 600 nm. Fluo-3 ﬂuorescence was recorded in the
line-scan mode of the confocal microscope (Olympus Fluoview
1000). The myocytes were ﬁeld-stimulated using extracellular
platinum electrodes.
Patch-clamp recordings
For the voltage-clamp experiments the external solution
contained in mmol/L: 140 NaCl, 5.4 CsCl, 2.0 CaCl2, 0.5
MgCl2, 10 HEPES, and 5.6 glucose (pH 7.4). Patch pipettes
were ﬁlled with a solution that contained in mmol/L: 123
CsCl, 20 TEACl, 5 MgATP, 5 NaCl, 1 MgCl2, 0.1 Tris GTP, 10
HEPES, and 0.1 Rhod-2 K-salt (Molecular Probes, OR) (pH
7.2). Rhod-2 dye was excited with 561 nm laser and
ﬂuorescence was collected at 570 to 620 nm wavelengths.
Ca currents and corresponding Ca transients were evoked by
300 ms depolarizing steps from 50 to 40 . . . 60 mV in
10 mV intervals. The excitation-contraction (EC) coupling gain
was calculated as a ratio of Ca transient amplitude to the
peak density of Ca current.
Ca imaging in permeabilized myocytes
The myocytes were permeabilized with saponin (0.01% for
50 seconds) dissolved in the internal solution, which con-
tained (mmol/L): 120 potassium aspartate, 20 KCl, 0.81
MgCl2, 1 KH2PO4, 0.1 EGTA, (free [Ca] 120 nmol/L),
20 lmol/L cAMP, 3 MgATP, 10 phosphocreatine, 20 Hepes
(pH 7.2) and 5 U/mL creatine phosphokinase. The cells were
incubated with either WT or mutant CaM for 25 minutes to
allow equilibration of CaM binding to its targets. Ca sparks
were detected and analyzed using a custom MATLAB (2014b,
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The MathWorks, Inc, MA) script as described previously.30
Refractoriness factor (RF), calculated as the inverse of
frequency of Ca sparks that occurred within 1 seconds
following Ca wave, was used to characterize refractoriness of
the SR Ca release.
Statistical Analysis
Results are expressed as MeanSEM. Statistical signiﬁcance
was determined using either one-way ANOVA or unpaired
Student t test. For certain data sets with smaller sample size,
The Wilcoxon rank sum or Kruskal–Wallis test was applied. A
P<0.05 was considered statistically signiﬁcant.
Results
CPVT CaM Mutants Shorten RyR2 Refractoriness
Genetic causes of certain forms of CPVT (eg, mutations in the
luminal RyR2 accessory protein CASQ2) involve premature
reactivation of RyR2 via abbreviation of the time RyR2 remains
refractory.7 Recently, mutations in CaM have also been shown
to cause CPVT.31–33 Considering CaM binding to the cytosolic
surface of RyR2 has been reported to contribute to inactivation
of RyR2,17–20 we tested whether arrhythmogenic mutations of
CaM also act by shortening RyR2 refractoriness. Ca imaging
was performed in permeabilized cardiacmyocytes (cytosolic Ca
buffered at 120 nmol/L) supplemented with different CaM
protein variants.34,35 Consistent with previous studies,31 the
addition of the CPVT CaM N98S (100 nmol/L), to permeabi-
lized myocytes isolated from WT mice signiﬁcantly increased
the frequency of Ca waves (as compared with WT CaM;
Figure 1A and 1C). RyR2 refractoriness in permeabilized
myocytes was assessed by examining sparks restitution
following Ca waves.9,36 Ca sparks restitution was accelerated
by CaMN98S, as indicated by the increased Ca spark frequency
following a Ca wave (Figure 1B and 1C). Refractoriness factor
(RF) was calculated as inverse to spark frequency occurring
within 1-second following Ca wave. RyR2 refractoriness was
signiﬁcantly shortened by CaM N98S compared with WT CaM
(Figure 1C). Similar results were obtained with the CPVT CaM
N54I (Figure S1). Together with previous results on CASQ2 and
RyR2-mediated CPVT, these data suggests that shortened RyR2
refractoriness may be a common mechanism that promotes
arrhythmias caused by both CASQ2 and CaM mutants.7,8
To determine whether these two different regulators of
RyR2 are additive or if they operate independently, we
examined the impact of arrhythmogenic CaMs in myocytes
derived from CPVT mice devoid of CASQ2 (CASQ2-KO).23 As
expected, in the presence of WT CaM permeabilzed CASQ2-
KO myocytes displayed signiﬁcantly higher frequency of Ca
waves when compared with myocytes from WT animals
(0.540.01 versus 0.370.02 per seconds, P<0.001).
Notably, supplementation of permeabilized CPVT myocytes
with CaM N98S further increased the frequency of Ca waves
and shortened the refractory period in these cells (Figure 2).
Thus, CPVT mutations in CaM and CASQ2 act in parallel to
modulate RyR2 refractoriness. These results suggest that it
may be possible to modulate the composite RyR2 refractori-
ness by targeting either one of these proteins. We examined
the possibility of modulating RyR2 refractoriness through
modifying the Ca-binding properties of CaM.
Figure 1. CPVT CaM N98S increased Ca wave frequency and
shortened RyR2 refractoriness. A, representative line-scan
images of spontaneous Ca waves (SCWs) in permeabilized WT
myocytes exposed to 100 nmol/L wtCaM or 100 nmol/L CPVT
CaM N98S. Cytosolic Ca was clamped at 120 nmol/L with the
slow Ca buffer EGTA. B, time-dependent recovery of Ca sparks
after occurrence of SCWs. Frequency of Ca sparks (f sparks)
was calculated at 200 ms intervals. Recovery of Ca sparks was
ﬁtted with mono-exponential curve with tau of 0.25 seconds for
wtCaM and 0.07 seconds for N98S CaM, respectively. Ca
sparks steady state levels (f0) were 0.7 (per 100 lm per second)
for wtCaM and 1.6 (per 100 lm per second) for N98S CaM,
respectively. C, Average data for SCW frequency, Ca spark
frequency and refractoriness factor (RF) obtained from WT
mouse ventricular myocytes permeabilized with wild-type (wt)
and CPVT (N98S) CaMs, respectively, n=38 to 58 cells, *P<0.05
vs wtCaM. Ca indicates calcium; CaM, calmodulin; CPVT,
catecholaminergic polymorphic ventricular tachycardia; EGTA,
ethylene glycol-bis(b-aminoethyl ether)-N,N,N0,N0-tetraacetic
acid; RF, refractoriness factor; RyR2, ryanodine receptor 2;
SCW, spontaneous Ca waves; WT, wild type.
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Modulating RyR2 Refractoriness Via Tuning Ca
Binding to CaM
Structurally CaM is thought to be composed of a C-terminal
domain that controls the docking of CaM to RyR2 and an
N-terminal domain that governs the Ca-dependent regulation
of RyR2 by CaM (Figure 3A).37–39 Based on this model, we
hypothesized that altering (ie, accelerating or slowing) the
release of Ca from the N-terminal domain of CaM should
accordingly change CaM’s ability to help keep RyR2 refractory
during diastole. To test this hypothesis we measured CaM Ca
dissociation in vitro in WT and mutant recombinant CaM
protein (Figure 3B and 3C). Since association with target
proteins is known to inﬂuence CaM’s Ca binding kinetics,40
we performed experiments with the CaMs alone (Figure 3B)
and CaMs complexed with a peptide corresponding to the
CaM binding domain of RyR241 (CaM-pRyR2) (Figure 3C). In
accordance with our prediction, the CPVT associated mutation
N54I accelerated the rate of Ca dissociation from the
N-domain of isolated CaM (Figure 3B). Furthermore, the
N54I mutation, in addition to shortening RyR2 refractoriness
(Figure S1) accelerated the N-terminal rate of Ca dissociation
from CaM when complexed with the RyR2 peptide
(Figure 3C). In the presence of the target peptide, the values
of the Ca dissociation rates (ranging from 10.6 to 19.0/
second) were now comparable to Ca spark restitution rates in
myocytes in the presence of the corresponding CaM variants
(3/second).
To test further the notion that the rate of Ca dissociation
from CaM’s N-domain contributes to CaM regulation of RyR2
refractoriness, a CaM construct (CaM D57A) with hindered
ability to bind Ca at the N-terminal was engineered and its effect
on SR Ca release was examined. The D to A point mutation in
CaM at position 57 (CaM D57A) greatly accelerated the Ca
dissociation from the N-terminal domain of CaM (Figure 4A).
Similar to the CPVT CaMs, supplementation of CaMD57A toWT
myocytes signiﬁcantly increased the frequency of Ca waves,
and shortened RyR2 refractoriness compared with WT CaM
(Figure 4B and 4C). Thus, RyR2 refractoriness can be modu-
lated by altering the N-terminal Ca dissociation rate of CaM.
This property of CaM makes it an excellent therapeutic target
for resetting CPVT associated abbreviated RyR2 refractoriness.
Engineered Therapeutic CaMs
Based on the above mentioned results, stabilizing Ca binding
to CaM by slowing its rate of dissociation should prolong
refractoriness and may potentially be therapeutic against
arrhythmias. To slow CaM’s N-terminal rate of Ca dissociation,
we stabilized its Ca binding induced open conformation by
mutating a key hydrophobic residue, Met 37, into a polar
residue Gln. Based on our previous studies on CaM’s
evolutionary relative troponin C, a similar mutation in troponin
C facilitates the Ca-induced structural transition of the
protein, thus stabilizing Ca binding.42,43 As shown in
Figure 5A, mutating Met 37 to Gln (CaM M37Q) drastically
slowed the rate of N-terminal Ca dissociation from CaM. As
predicted, addition of CaM M37Q to permeabilized CPVT
myocytes (CASQ2 R33Q44) reduced Ca waves (Figure 5B and
5C), and prolonged the refractory period of RyR2 (Figure 5C)
relative to WT CaM.
Previous reports have suggested that aberrant RyR2 Ca
release in myocytes derived from failing hearts can be blunted
by addition of a CaM with enhanced binding afﬁnity to RyR2,
GSH-CaM.45,46 Unexpectedly, the addition of GSH-CaM to the
CPVT myocytes had no effect at preventing the adverse Ca
waves and accordingly had no signiﬁcant effect at prolonging
the pathologically abbreviated refractory period in these
myocytes (Figure 5B and 5C). However, the addition of GSH
to the N-terminus of CaM M37Q to help target our engineered
CaM to RyR2 markedly enhanced its potentially beneﬁcial
effects in the CASQ2 R33Q myocytes (Figure 5B and 5C). One
could surmise that prolonging refractoriness with this GSH-
M37Q-CaM (termed therapeutic CaM [TCaM]) in CPVT mice
harboring the arrhythmogenic CASQ2 R33Q mutation would
Figure 2. CPVT CaM N98S increased Ca waves frequency and
shortened RyR2 refractoriness in CASQ2 KO myocytes. A,
representative line-scan images of SCWs in permeabilized CASQ2
KO myocytes exposed to either 100 nmol/L of wtCaM or
100 nmol/L of N98S CaM. Cytosolic Ca was clamped at
120 nmol/L with the slow Ca buffer EGTA. B, Average data
for SCW frequency and refractoriness factor obtained from
CASQ2 KO ventricular myocytes permeabilized with 100 nmol/L
wtCaM and 100 nmol/L of N98S CaM, respectively, n=31 to 38
cells, *P<0.05 vs wtCaM. Ca indicates calcium; CaM, calmodulin;
CASQ2, calsequestrin; CPVT, catecholaminergic polymorphic
ventricular tachycardia; EGTA, ethylene glycol-bis(b-aminoethyl
ether)-N,N,N0,N0-tetraacetic acid; KO, knock out; RyR2, ryanodine
receptor 2; SCW, spontaneous Ca waves.
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be anti-arrhythmic in vivo. This hypothesis can be tested in
mice harboring the CPVT CASQ2 R33Q mutation.
Viral-Mediated Gene Delivery of TCaM Alleviates
Arrhythmia Burden in CPVT
In order to incorporate TCaM into the murine heart, we
generated an AAV9-TCaM viral construct which was injected
transthoracically into CPVT R33Q mice. The construct also
contained a sequence encoding mCherry for transfection
veriﬁcation.24 Figure 6A demonstrates that 40% of the
ventricular myocytes could be transduced with our viral
construct based on mCherry ﬂuorescence. Consistent with
the CPVT phenotype, myocytes isolated from R33Q mice
transfected with our control mCherry AAV9 virus displayed
frequent diastolic Ca waves, when stimulated at 0.5 Hz in the
Figure 3. The effect of CPVT CaM N54I on the rate of Ca dissociation from N-domain of CaM. A, Ca
bound N-domain of CaM binds RyR2 and keeps it refractory following CICR. Meanwhile, CASQ2 senses
luminal (Ca) decrease and contributes to RyR2 refractoriness. B, the time course of the decrease in Trp
ﬂuorescence as Ca dissociated from CaMF20W constructs. The data traces have been staggered and
normalized for clarity. C, the time course of the increase in Quin-2 ﬂuorescence as Ca dissociated from
CaM-pRyR2 complex. The data traces have been staggered and normalized for clarity. Ca indicates, calcium;
CaM, calmodulin; CASQ2, calsequestrin; CICR, calcium induced calcium release; CPVT, catecholaminergic
polymorphic ventricular tachycardia; RyR2, ryanodine receptor 2; Trp, tryptophan.
DOI: 10.1161/JAHA.117.008155 Journal of the American Heart Association 6
Gene Transfer of Calmodulin Alleviates CPVT Liu et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
ay 10, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
presence of 100 nmol/L isoproterenol, a b-adrenergic ago-
nist (Figure 6B). Notably, the frequency of these arrhythmo-
genic events was markedly reduced (6-fold) in AAV9-TCaM
myocytes (Figure 6B and 6C). Additionally, RyR2 refractori-
ness was signiﬁcantly prolonged in AAV9-TCaM myocytes
consistent with the results obtained in permeabilized
myocytes (Figure 6C). Therefore, TCaM alleviated cellular
arrhythmogenesis in intact myocytes isolated from AAV9
infected R33Q mice. Of note, TCaM did not alter Ca transient
amplitude, baseline cytosolic Ca (Figure 6D) or the extent of
shortening in the same myocytes (Figure S2). Moreover TCaM
had no signiﬁcant impact on inward Ca currents, Ca transients
and EC coupling gain in patch clamped R33Q myocytes
(Figure S3). Thus, while inhibiting arrhythmogenic diastolic Ca
waves, TCaM did not signiﬁcantly alter EC coupling, systolic
Ca release or contractile function in R33Q myocytes.
To test the ability of AAV9-TCaM to reduce arrhythmia
propensity in vivo, we performed surface ECG measurements
in anesthetized CASQ2 R33Q mice challenged with epinephr-
ine (Epi)+caffeine (Caf).27 Following IP injection of Epi and Caf,
only 10% of WT control mice developed episodes of VT, but
nearly all untransfected CASQ2 R33Q mice exhibited CPVT
(Figure 7A and 7B). Additionally, 7 out of 8 (88%) of these
mice died following arrhythmia induction. Notably, the AAV9-
TCaM infected mice had markedly reduced incidence of VT
following epinephrine and caffeine challenge. Moreover, the
majority of the mice, 7 out of 8 (88%), survived following the
Epi/Caf injection (Figure 7C). Thus, our rationally engineered
therapeutic protein, TCaM, alleviated life threatening ventric-
ular arrhythmias in the CASQ2 R33Q mice in vivo.
Discussion
In this study, we provided evidence that rationally engineered
CaM can be delivered to CPVT mice to treat arrhythmias. In
particular, we demonstrated that therapeutic CaM proteins
can be designed that interact with RyR2 to prolong its
refractoriness (ie, ability to stay appropriately closed during
diastole) which is abnormally shortened in CPVT. Importantly,
application of such a TCaM normalized myocyte Ca cycling
and reduced in vivo arrhythmia in mice affected by a mutation
that occurs in another disease-related protein (CASQ2). Thus,
TCaMs may provide a therapeutic strategy for multiple genetic
forms of CPVT and potentially other forms of Ca-dependent
arrhythmias associated with altered RyR2 function.
Following a Ca transient Ca release channels become
inactivated and remain unresponsive for a certain time
interval termed mechanical/Ca refractory period.36,47 Refrac-
toriness is modulated by a number of different factors,
including luminal Ca, CASQ2,21,48–50 RyR2 phosphorylation
and oxidation states.51–53 Here we demonstrated that this
process is also inﬂuenced by CaM and cytosolic Ca (Figure 8).
Moreover, we showed that a CaM protein, ie, TCaM, designed
to enhance RyR2 refractoriness can normalize pathologically
abbreviated refractoriness to inhibit arrhythmogenesis in
CPVT.
The potential role of CaM in regulating RyR2 has long been
recognized.17–20 CaM is associated with RyR2 at its cytosolic
regulatory domain and inhibits RyR2 activity at elevated Ca.18
Recently several mutations of CaM have been linked to
cardiac arrhythmia and speciﬁcally to CPVT.31 However,
precisely how and through what molecular steps CaM
regulates RyR2 mediated SR Ca release in cardiomyocytes
and how these processes are altered to cause arrhythmia
Figure 4. Engineered CaM variant D57A exhibited a faster rate
of Ca dissociation and mimicked the effects of CPVT CaMs. A, the
time course of the decrease in Trp ﬂuorescence as Ca dissociated
from CaMF20W constructs. The data traces have been staggered
and normalized for clarity. B, representative line-scan images of
SCWs in permeabilized WT myocytes exposed to 100 nmol/L
wtCaM or 100 nmol/L D57A CaM. Cytosolic Ca was clamped at
120 nmol/L with the slow Ca buffer EGTA. C, Average data for
SCW frequency and refractoriness factor obtained from WT
mouse ventricular myocytes permeabilized with wtCaM and D57A
CaM, respectively, n=40 cells, *P<0.05 vs wtCaM. Ca indicates
calcium; CaM, calmodulin; cAMP, cyclic adenosine monophos-
phate; EGTA, ethylene glycol-bis(b-aminoethyl ether)-N,N,N0,
N0-tetraacetic acid; SCW, spontaneous Ca waves; TCaM, thera-
peutic calmodulin; Trp, tryptophan; WT, wild type.
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remains to be elucidated. Here, we demonstrated that CaM
contributes to RyR2 refractoriness through binding of Ca to
CaM’s N-terminal domain and subsequent inhibition of RyR2
following SR Ca release. In support of this conclusion
engineered mutations that accelerated Ca dissociation from
the N-terminal domain of CaM shortened RyR2 refractoriness
whereas engineered mutations that slowed Ca dissociation
prolonged RyR2 refractoriness in permeabilized myocytes
(Figures 4 and 5). Moreover, we also demonstrated that
impairment of this regulatory mechanism accounts for arrhyth-
mogenesis in CaM-dependent CPVT. In particular, our exper-
iments showed that CPVT mutations in CaM accelerated Ca
dissociation from the N-terminal domain of CaM and shortened
RyR2 refractoriness (Figures 1 and 3; Figure S1). These ﬁndings
are supported also by previous results of Sondergaard et al
who showed that CPVT CaM N54I increased the rate of Ca
dissociation from N-domain of CaM.54
We and others have previously demonstrated that the
generation of arrhythmogenic Ca release in CPVT involves
shortened refractoriness of RyR2 in CPVT models associated
with mutations in CASQ2.7,21 CPVT mutations in CaM and
CASQ2 produced additive effects on RyR2 refractoriness and
cellular arrhythmogenesis, supporting the notion that short-
ened refractoriness is a common mechanistic step in CPVT
(Figure 2). Given the general role of RyR2 refractoriness in
arrhythmogenesis, we reasoned that normalizing shortened
RyR2 refractoriness by a rationally designed CaM with
enhanced ability to induce RyR2 refractoriness may provide
a therapeutic strategy for genetically distinct forms of CPVT.
We were able to test this hypothesis by designing a
therapeutic CaM that possessed a slowed N-terminal domain
Ca dissociation rate and whose binding to RyR2 was
enhanced by the GSH tag attached to the N-terminus of the
protein. Introduction of this TCaM into permeabilized
myocytes derived from mice affected by CASQ2-dependent
CPVT normalized shortened refractoriness and reduced the
frequency of diastolic Ca waves in these cells. Moreover viral-
mediated transthoracic delivery of TCaM to adult CASQ2
R33Q mice reduced myocyte arrhythmic potential, in vivo
susceptibility to arrhythmias and death in these mice.
Figure 5. TCaM signiﬁcantly reduced spontaneous Ca waves in permeabilized R33Q myocytes and
prolonged refractoriness. A, the time course of the decrease in Trp ﬂuorescence as Ca dissociated from
CaMF20W constructs. The data traces have been staggered and normalized for clarity. B, representative line-
scan images of SCWs in permeabilized R33Q myocytes exposed to cAMP. Cytosolic Ca was clamped at
120 nmol/L with the slow Ca buffer EGTA. C, Average data for SCW frequency (n=18–39 cells) and
refractoriness factor (n=11–15 cells) obtained from R33Q ventricular myocytes permeabilized with wtCaM,
GSH-CaM, M37Q CaM, and GSH-M37Q CaM (TCaM), *P<0.05 vs wtCaM. Ca indicates calcium; CaM,
calmodulin; cAMP, cyclic adenosine monophosphate; EGTA, ethylene glycol-bis(b-aminoethyl ether)-N,N,N0,
N0-tetraacetic acid; SCW, spontaneous Ca waves; TCaM, therapeutic calmodulin; Trp, tryptophan; WT, wild
type.
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Recent studies from Priori and coworkers55,56 demon-
strated that wild type CASQ2 gene replacement utilizing AAV
can rescue a CPVT phenotype associated with a mutated or
absent CASQ2. However, such wild type replacement-gene
transfer has the limitation that it can tackle only the subset of
CPVT disorders dependent on aberrant CASQ2. Here we
demonstrated that an engineered gene transfer of the RyR2
regulatory protein CaM can counter a non-CaM modulated
arrhythmia model, suggesting that this therapeutic TCaM
approach may serve as a general therapeutic avenue for CPVT
mutations that result in aberrant Ca release. We have
previously shown that abnormally shortened RyR2 refractori-
ness contributes to arrhythmogenesis associated with altered
posttranslational modiﬁcations of RyR2 in settings of acquired
cardiac disease, including post-infarction VF and non-ischemic
heart failure.9,53,57 TCaMs could potentially serve as a general
therapeutic approach to alleviate arrhythmia caused by
various genetic and acquired molecular defects in the RyR2
channel complex.
It should be noted that TCaM proved highly effective at
preventing arrhythmia despite a moderate transfection efﬁ-
cacy (40% myocytes transfected). Priori et al noted a similar
unexpectedly high antiarrhythmic potential in the face of low
transfection efﬁcacy of virally transferred WT CASQ2.55,56 The
unexpectedly strong antiarrhythmic effects of this delivery
method could be explained by considering the role of
synchronization of aberrant diastolic SR Ca release in the
genesis of Ca-dependent arrhythmia. In order to initiate
triggered activity in the form of triggered action potentials,
aberrant Ca release has to occur synchronously across a
critical mass of myocardium. We recently demonstrated that
diastolic Ca release is indeed highly synchronized in CPVT
ventricular myocytes7 and in cardiac tissue, due in part to
Figure 6. TCaM infected R33Q myocytes had improved Ca
handling. A, evaluation of the infection efﬁciency of TCaM: phase
contrast and mCherry ﬂuorescence of TCaM injected R33Q
myocytes. B, representative line-scan images of SCWs in intact
myocytes isolated from mCherry or TCaM virus infected R33Q
mouse. Myocytes were ﬁeld-stimulated at 0.3 Hz in the presence
of 1 lmol/L isoproterenol. C, Average data for SCW frequency
(n=45–50 cells) and refractoriness factor (n=15–17 cells)
obtained from R33Q myocytes infected with control (mCherry)
and TCaM virus, respectively, *P<0.05 vs mCherry. D, Average of
Ca transient amplitude and baseline ﬂuorescence obtained from
R33Q myocytes infected with control (mCherry) and TCaM virus,
respectively, *P<0.05 vs mCherry. Ca indicates calcium; TCaM,
therapeutic calmodulin; SCW, spontaneous Ca waves.
Figure 7. TCaM alleviated ventricular tachycardia in vivo in
CPVT mice R33Q. A, Representative surface ECG traces from WT
mice, R33Q mice or R33Q mice treated with TCaM. B, Average of
VT incidence, n=8 to 19, *P<0.05 vs R33Q, #P<0.05 vs WT. C,
Percentage of survival after ECG n=8 to 19, *P<0.05 vs R33Q,
#P<0.05 vs WT. CPVT indicates catecholaminergic polymorphic
ventricular tachycardia; ECG, electrocardiogram; TCaM, therapeu-
tic calmodulin; VT, ventricular tachycardia.
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abnormally abbreviated Ca release refractoriness.7 Therefore,
slowing Ca release refractoriness with TCaMs is expected to
reduce the incidence of synchronized aberrant Ca release
events on the cellular level, thus reducing triggered activity in
tissue and arrhythmias in vivo.
In summary, this study demonstrates that a smartly
formulated CaM variant designed to prolong RyR2 refractori-
ness inhibits arrhythmogenic aberrant Ca release in myocytes
derived from CPVT hearts. Importantly, adenoviral-mediated
thoracic cavity delivery of this CaM alleviated CPVT episodes
and death in vivo. Our study points to a new therapeutic
strategy for CPVT and possibly other forms of Ca-dependent
arrhythmias using rationally engineered CaMs. Although we
are discovering common aberrant mechanisms for arrhyth-
mias, not all diseased hearts have the same etiology, genetic
background or co-morbidities. Designer proteins open the
doors for unprecedented personalized, and potentially, even
generalized medicines as gene therapy or protein delivery
techniques come to fruition.
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